

Texas Providers Webinar Highlights – November 30, 2021

Read below for topics covered or view the [full recording](#) for detailed information.

COVID-19 Booster Eligibility Update

- On Monday, November 29th the CDC strengthened its recommendation on booster doses for individuals who are 18 years and older. **Everyone ages 18 and older should get a booster shot** either when they are **6 months** after their initial Pfizer or Moderna series or **2 months** after their initial J&J vaccine. For more information, please review the [CDC's COVID-19 booster recommendations](#) and [DSHS' COVID-19 booster infographic](#).

COVID-19 CDC Updates

- Should you experience any issues with the supplies included within the ancillary kits that are shipped to your facility, please report deficiencies to **McKesson** directly by email at CDCCustomerService@McKesson.com and to the **State Department of Health or clinic/hospital leadership**. If an error or injury occurs during vaccine administration, enter the information into [VAERS](#). Finally, because syringes are a medical device, complete [FDA form 3500](#).
- CDC has received several questions regarding use of syringes with 0.2 mL tick marks to draw up doses of Moderna booster vaccine (0.25mL) and Pfizer pediatric diluent (1.3mL). ACIP and CDC do not yet have any official guidance on this issue. When using syringes that have tick marks at the 0.2 mL interval, providers are advised to use their best judgment to draw up half-way between tick marks to extract the proper volume.

Day in the Life of a COVID-19 Vaccine Administrator

- Access the [CDC's COVID-19 Vaccine Product Information Guide](#) for important information about ancillary kits, administration, storage, mixing kits, needles and syringes, and more.
- To ensure you are following proper storage guidelines for each vaccine presentation, please review the COVID-19 Vaccine EUAs for [Pfizer 5-11](#), [Pfizer 12+](#), [Moderna](#), and [Janssen](#) formulations.

ImmTrac2 Reporting

- Providers may use the Rapid Entry tool in ImmTrac2 when entering COVID immunizations without consents, when reporting Pfizer boosters, and when reporting pediatric doses. Priority Group Code **GPT2** should be used for household contacts of infants <6 months and for children 3-18 years with high-risk conditions. Priority Group Code **GPT3** should be used for children 3-18 years without high-risk conditions.
- Please use trade name "**Comirnaty TS, 10mcg/0.2mL**" when reporting COVID-19 vaccine doses **for ages 5-11 years** and use trade name "**Pfizer COVID-19 Vaccine**" for **ages 12+ years**.

COVID-19 Vaccine Ordering

- Pfizer has announced that there will be **no expiration extension** for lots of Pfizer COVID-19 vaccine that are scheduled to expire on November 30th. Please dispose of any expired vaccine in accordance with CDC's [vaccine waste disposal guidelines](#) and [report vaccine waste in VAOS](#).

Provider Resources:

- [COVID-19 Vaccine Management Resources \(training and support materials\)](#)
- [ImmTrac2 User Training Site](#)
- [ImmTrac2 Forms and Documents](#)
- [COVID-19 Vaccine Provider Enrollment Information](#)
- [CDC Clinical Considerations for or Use of mRNA COVID-19 Vaccines](#)
- DSHS Provider Help Desk: (833) 832-7068, 8 a.m. to 5 p.m., Monday through Friday; Email: COVID19VacEnroll@dshs.texas.gov

Session Live Q&A:

- Is it appropriate to administer a dose of pediatric COVID-19 vaccine two days before the three-week interval?
- What are the current guidelines for patients who received AstraZeneca's two dose series and would like to receive a Moderna/Pfizer booster dose?
- If a vial has expired without being punctured, do we need to report the doses as waste in VAOS? Do we need to send the vials back to the manufacturer?
- Can a patient refuse to have their COVID-19 vaccine administration entered in ImmTrac2?
- Are there specific consent forms we should be using when we administer COVID-19 vaccines?

